Ray Dalio's AZN Position Overview
Ray Dalio (via Bridgewater Associates, Lp) currently holds 8,188 shares of AstraZeneca PLC (AZN) worth $1.32 M, representing 0.01% of the portfolio. First purchased in 2021-Q2, this medium-term investment has been held for 20 quarters.
Based on 13F filings, Ray Dalio has maintained a strategic position in AZN, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2024, adding 234,176 shares. Largest reduction occurred in Q4 2025, reducing 231,430 shares.
Analysis based on 13F filings available since 2013 Q2
Ray Dalio's AstraZeneca PLC (AZN) Holding Value Over Time
Track share changes against reported price movement
Quarterly AstraZeneca PLC (AZN) Trades by Ray Dalio
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q3 2026 | +8,188 | New Buy | 8,188 | $161.47 |
| Q4 2025 | -231,430 | Sold Out | 0 | $0.00 |
| Q3 2025 | -79,022 | Reduce 25.45% | 231,430 | $153.44 |
| Q2 2025 | -35,098 | Reduce 10.16% | 310,452 | $139.76 |
| Q1 2025 | +8,820 | Add 2.62% | 345,550 | $147.00 |
| Q4 2024 | +234,176 | Add 228.34% | 336,730 | $131.04 |
| Q3 2024 | -2,034 | Reduce 1.94% | 102,554 | $155.82 |
| Q2 2024 | +54,957 | Add 110.73% | 104,588 | $155.98 |
| Q1 2024 | -30,394 | Reduce 37.98% | 49,631 | $135.50 |
| Q4 2023 | +23,121 | Add 40.63% | 80,025 | $134.70 |
| Q3 2023 | +2,024 | Add 3.69% | 56,904 | $135.44 |
| Q2 2023 | +6,074 | Add 12.45% | 54,880 | $143.14 |
| Q1 2023 | +3,997 | Add 8.92% | 48,806 | $138.82 |
| Q4 2022 | +4,913 | Add 12.31% | 44,809 | $135.60 |
| Q3 2022 | +4,395 | Add 12.38% | 39,896 | $109.69 |
| Q2 2022 | -2,792 | Reduce 7.29% | 35,501 | $132.14 |
| Q1 2022 | +1,847 | Add 5.07% | 38,293 | $132.69 |
| Q4 2021 | -15,670 | Reduce 30.07% | 36,446 | $116.50 |
| Q3 2021 | +6,448 | Add 14.12% | 52,116 | $120.12 |
| Q2 2021 | +45,668 | New Buy | 45,668 | $119.80 |
Ray Dalio's AstraZeneca PLC Investment FAQs
Ray Dalio first purchased AstraZeneca PLC (AZN) in Q2 2021, acquiring 45,668 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio has held AstraZeneca PLC (AZN) for 20 quarters since Q2 2021.
Ray Dalio's largest addition to AstraZeneca PLC (AZN) was in Q4 2024, adding 336,730 shares worth $44.13 M.
According to the latest 13F filing for Q3 2026, Ray Dalio's firm, Bridgewater Associates, Lp, owns 8,188 shares of AstraZeneca PLC (AZN), valued at approximately $1.32 M.
As of the Q3 2026 filing, AstraZeneca PLC (AZN) represents approximately 0.01% of Ray Dalio's publicly disclosed stock portfolio, making it one of their key holdings.
Ray Dalio's peak holding in AstraZeneca PLC (AZN) was 345,550 shares, as reported at the end of Q1 2025.